Reported Earnings • May 28
First quarter 2026 earnings released: RM0.003 loss per share (vs RM0.001 profit in 1Q 2025) First quarter 2026 results: RM0.003 loss per share (down from RM0.001 profit in 1Q 2025). Revenue: RM48.9m (down 16% from 1Q 2025). Net loss: RM2.61m (down 489% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. New Risk • May 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Malaysian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (RM104.0m market cap, or US$26.2m). Annonce • Apr 24
K-One Technology Berhad, Annual General Meeting, May 26, 2026 K-One Technology Berhad, Annual General Meeting, May 26, 2026, at 09:00 Singapore Standard Time. Location: ballroom v, main wing, tropicana golf & country resort, jalan kelab tropicana, 47410 petaling jaya, selangor, Malaysia New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Malaysian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (RM95.7m market cap, or US$24.3m). Reported Earnings • Feb 26
Full year 2025 earnings released: EPS: RM0 (vs RM0 in FY 2024) Full year 2025 results: EPS: RM0 (in line with FY 2024). Revenue: RM243.2m (up 21% from FY 2024). Net income: RM268.0k (up 33% from FY 2024). Profit margin: 0.1% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 9% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 27
Third quarter 2025 earnings released: RM0.001 loss per share (vs RM0.002 loss in 3Q 2024) Third quarter 2025 results: RM0.001 loss per share (improved from RM0.002 loss in 3Q 2024). Revenue: RM56.6m (down 2.4% from 3Q 2024). Net loss: RM494.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Nov 21
Now 21% undervalued Over the last 90 days, the stock has risen 17% to RM0.14. The fair value is estimated to be RM0.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Nov 04
Now 20% undervalued Over the last 90 days, the stock has risen 13% to RM0.14. The fair value is estimated to be RM0.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. New Risk • Oct 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Malaysian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (RM137.3m market cap, or US$32.4m). Reported Earnings • Aug 27
Second quarter 2025 earnings released: EPS: RM0 (vs RM0.001 in 2Q 2024) Second quarter 2025 results: EPS: RM0 (down from RM0.001 in 2Q 2024). Revenue: RM64.5m (up 44% from 2Q 2024). Net income: RM320.0k (down 68% from 2Q 2024). Profit margin: 0.5% (down from 2.3% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. New Risk • Jun 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Malaysian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (RM108.2m market cap, or US$25.5m). Reported Earnings • May 29
First quarter 2025 earnings released: EPS: RM0.001 (vs RM0.002 in 1Q 2024) First quarter 2025 results: EPS: RM0.001 (down from RM0.002 in 1Q 2024). Revenue: RM58.5m (up 30% from 1Q 2024). Net income: RM670.0k (down 63% from 1Q 2024). Profit margin: 1.1% (down from 4.1% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Annonce • Apr 28
K-One Technology Berhad, Annual General Meeting, May 28, 2025 K-One Technology Berhad, Annual General Meeting, May 28, 2025, at 09:00 Singapore Standard Time. Location: ballroom v, main wing, tropicana golf & country resort, jalan kelab tropicana, selangor, 47410 petaling jaya Malaysia Reported Earnings • Feb 27
Full year 2024 earnings released: EPS: RM0 (vs RM0 in FY 2023) Full year 2024 results: EPS: RM0 (in line with FY 2023). Revenue: RM201.7m (up 21% from FY 2023). Net income: RM201.0k (down 43% from FY 2023). Profit margin: 0.1% (down from 0.2% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Nov 27
Third quarter 2024 earnings released: RM0.002 loss per share (vs RM0.002 loss in 3Q 2023) Third quarter 2024 results: RM0.002 loss per share (in line with 3Q 2023). Revenue: RM58.0m (up 37% from 3Q 2023). Net loss: RM2.04m (loss widened 2.9% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2023) Second quarter 2024 results: EPS: RM0.001 (up from RM0 in 2Q 2023). Revenue: RM44.8m (up 3.6% from 2Q 2023). Net income: RM1.01m (up RM990.0k from 2Q 2023). Profit margin: 2.3% (up from 0% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Annonce • Jul 01
K-One Technology Berhad Announces Resignation of Wong Youn Kim as Company Secretary K-One Technology Berhad announced resignation of Wong Youn Kim as Company Secretary. License No. is MAICSA 7018778. Date Of Change is 01 July 2024. Reported Earnings • May 28
First quarter 2024 earnings released: EPS: RM0.002 (vs RM0.001 loss in 1Q 2023) First quarter 2024 results: EPS: RM0.002 (up from RM0.001 loss in 1Q 2023). Revenue: RM44.9m (up 9.6% from 1Q 2023). Net income: RM1.82m (up RM2.25m from 1Q 2023). Profit margin: 4.1% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annonce • Apr 27
K-One Technology Berhad, Annual General Meeting, Jun 19, 2024 K-One Technology Berhad, Annual General Meeting, Jun 19, 2024, at 09:00 Singapore Standard Time. Agenda: To receive the Audited Financial Statements for the financial year ended 31 December 2023 together with the Directors and Auditors Reports thereon;to approve the payment of Directors' fees to the Non-Executive Directors of up to RM240,000 from 19 June 2024 until the next Annual General Meeting of the Company, to be paid monthly in arrears after each month of completed service; to approve the payment of Directors' allowances to the Non-Executive Directors from 19 June 2024 until the next Annual General Meeting of the Company; to re-elect Ms Anita Chew Cheng Im who retires in accordance with Clause 106 of the Company's Constitution and being eligible, offers herself for re-election; and to consider other matters. New Risk • Mar 31
New major risk - Revenue and earnings growth Earnings have declined by 43% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RM124.8m market cap, or US$26.4m). Reported Earnings • Feb 27
Full year 2023 earnings released: EPS: RM0 (vs RM0 in FY 2022) Full year 2023 results: EPS: RM0 (in line with FY 2022). Revenue: RM167.2m (up 1.5% from FY 2022). Net income: RM351.0k (up RM451.0k from FY 2022). Profit margin: 0.2% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 28
Third quarter 2023 earnings released: RM0.002 loss per share (vs RM0.002 profit in 3Q 2022) Third quarter 2023 results: RM0.002 loss per share (down from RM0.002 profit in 3Q 2022). Revenue: RM42.5m (down 5.0% from 3Q 2022). Net loss: RM1.98m (down 209% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Malaysian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (RM120.6m market cap, or US$26.0m). Buying Opportunity • Oct 20
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 6.7%. The fair value is estimated to be RM0.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company has become profitable. Annonce • Sep 02
K-One Meditech Sdn Bhd Receives Approval from the Medical Device Authority Under the Ministry of Health, Malaysia for Registration of Diversey's Oxivir Excel Disinfectant Wipes Used for Cleaning Surfaces and Equipment The Board of Directors of K-One Technology Berhad announced that the Company's wholly-owned subsidiary, K-One MediTech Sdn Bhd has on 30 August 2023 received approval from the Medical Device Authority under the Ministry of Health, Malaysia for registration of Diversey's Oxivir Excel disinfectant wipes used for cleaning surfaces and equipment to be distributed in Malaysia. The K-One Group will sell the wipes in Malaysia as the exclusive distributor of Diversey (Malaysia) Sdn Bhd. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: RM0 (vs RM0.003 loss in 2Q 2022) Second quarter 2023 results: EPS: RM0 (improved from RM0.003 loss in 2Q 2022). Revenue: RM43.2m (up 23% from 2Q 2022). Net income: RM18.0k (up RM2.84m from 2Q 2022). Profit margin: 0% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 02
First quarter 2023 earnings released: EPS: RM0 (vs RM0.001 in 1Q 2022) First quarter 2023 results: EPS: RM0 (down from RM0.001 in 1Q 2022). Revenue: RM40.9m (up 7.4% from 1Q 2022). Net loss: RM425.0k (down 161% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: RM0 (vs RM0.003 loss in FY 2021) Full year 2022 results: EPS: RM0 (improved from RM0.003 loss in FY 2021). Revenue: RM165.4m (up 32% from FY 2021). Net loss: RM102.0k (loss narrowed 96% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Dec 04
Third quarter 2022 earnings released: EPS: RM0.002 (vs RM0.003 loss in 3Q 2021) Third quarter 2022 results: EPS: RM0.002 (up from RM0.003 loss in 3Q 2021). Revenue: RM44.7m (up 88% from 3Q 2021). Net income: RM1.81m (up RM4.22m from 3Q 2021). Profit margin: 4.1% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 5 highly experienced directors. Independent & Non Executive Director Edward Ka was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Sep 29
Medical Device Authority of Malaysia Grants Approval to K-One Meditech Sdn Bhd to Distribute Silicone Adhesive Tape Primarily Used for Wound Care Dressing The Board of Directors of K-One Technology Berhad announced that the Company’s wholly-owned subsidiary, K-One MediTech Sdn Bhd has on 27 September 2022 received approval from the Medical Device Authority under the Ministry of Health, Malaysia to distribute and sell silicone adhesive tapes primarily used for wound care dressing. The K-One Group will sell the silicone adhesive tapes in Malaysia as an authorized representative of Wuhan Huawei Technology Co. Ltd. which is the manufacturer based in China. Silicone Adhesive Tapes For Wound Care Applications & MDA Approval: The silicone adhesive tapes are advanced wound dressings which come in three product types. The first two product categories are applicable to a variety of indwelling catheters, electrodes or other external fixations that require gentle but robust skin protection and adhesion, while the third product type helps to improve scar appearance (including hypertrophic and keloid) and restores skin to a more natural color and texture. It also alleviates itchy skin and discomfort associated with scars. MDA has approved the distribution and sale of the above silicone adhesive tapes in three product categories for a period of five years from 26 September 2022 to 25 September 2027. The approval will provide the opportunity for the K-One Group to further expand its medical device business. The silicone adhesive tape wound dressing market is growing as its demand is anticipated to increase in tandem with the rising trend of surgeries performed in Malaysia (and abroad). Moreover, increasing awareness relating to the employment of medical tapes for securement among physicians and patients and the rising incidence of wounds, burns, injuries are anticipated to spice up the market demand. Annonce • Aug 25
K-One Technology Berhad Provides Impairment of Plant and Equipment for the Second Quarter Ended June 30, 2022 K-One Technology Berhad provided Impairment of plant and equipment for the second quarter ended June 30, 2022. For the period, the company reported Impairment of plant and equipment of MYR 1,643,000. Reported Earnings • Aug 25
Second quarter 2022 earnings released: RM0.003 loss per share (vs RM0.002 profit in 2Q 2021) Second quarter 2022 results: RM0.003 loss per share (down from RM0.002 profit in 2Q 2021). Revenue: RM35.2m (flat on 2Q 2021). Net loss: RM2.83m (down 300% from profit in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Annonce • Aug 18
Medical Device Authority (MDA) of Malaysia Approves COVID-19 Antigen Self-Test Kit (Saliva) for Distribution by K-One MediTech Sdn Bhd The Board of Directors of K-One Technology Berhad ("K-One Tech" or "Company" or "K-One Group") had on 27 October 2021 announced that the Medical Device Authority ("MDA") under the Ministry of Health, Malaysia had granted conditional approval for its wholly-owned subsidiary, K-One MediTech Sdn Bhd ("K-One MediTech") to import and distribute COVID-19 Antigen Self-Test Kit (Saliva) manufactured by Labnovation Technologies Inc, China ("Labnovation Tech") in Malaysia. The conditional approval is valid for a period of one year; from 26 October 2021 to 26 October 2022. Further to the above mentioned announcement, the Board of Directors of K-One Tech wishes to inform that K-One MediTech has on 17 August 2022 received approval with validity period extended to 14 August 2027 for the import and distribution of the said COVID-19 Antigen Self-Test Kit in Malaysia. As a recap, the COVID-19 Antigen Self-Test Kit (Saliva) is intended for the qualitative detection of SARS-CoV-2 antigen in human saliva samples from a COVID-19 suspected person. It is intended for self-testing and home use with the outcome of the test results known in 15 minutes. The use of the COVID-19 Antigen Self-Test Kit shall be for screening purpose and all test results require confirmation using the COVID-19 RT-PCR ("Reverse Transcription Polymerase Chain Reaction") test. The Board of K-One Tech is of the opinion that the extension of the validity period until 14 August 2027 for the distribution and supply of the said COVID-19 Self-Test Kit (Saliva) is in the best interest of the K-One Group. COVID-19 Antigen Self-Test Kits with MDA approvals are expected to be still in market demand despite the world claiming endemicity as COVID-19 lingers on with variants and sub-variants. The end of COVID-19 remains unclear. Reported Earnings • May 29
First quarter 2022 earnings released: EPS: RM0.001 (vs RM0.001 in 1Q 2021) First quarter 2022 results: EPS: RM0.001 (vs RM0.001 in 1Q 2021). Revenue: RM38.1m (up 23% from 1Q 2021). Net income: RM703.0k (down 39% from 1Q 2021). Profit margin: 1.8% (down from 3.7% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Azlam Bin Alias was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: RM0.003 loss per share (up from RM0.012 loss in FY 2020). Revenue: RM125.5m (up 38% from FY 2020). Net loss: RM2.70m (loss narrowed 69% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 26
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: RM0.003 loss per share (down from RM0.001 profit in 3Q 2020). Revenue: RM23.8m (flat on 3Q 2020). Net loss: RM2.41m (down RM2.93m from profit in 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 04
Second quarter 2021 earnings released: EPS RM0.002 (vs RM0.004 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RM35.0m (up 84% from 2Q 2020). Net income: RM1.42m (up RM4.27m from 2Q 2020). Profit margin: 4.0% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance. Annonce • Jun 09
K-One Technology Berhad Announces Approval of Low Dead Volume Syringes Suitable for Covid-19 Vaccination by Medical Device Authority, Malaysia The Board of Directors of K-One Technology Berhad announced that the K-One Group’s wholly owned subsidiary, K-One MediTech Sdn. Bhd. (fka K-One Resources Sdn. Bhd.) has on 4 June 2021 received approval from the Medical Device Authority ("MDA") under the Ministry of Health, Malaysia for the sale of Low Dead Volume disposable syringes with needle in Malaysia. The LDV syringes with needle are suitable for COVID-19 vaccinations to reduce vaccine wastage and applicable to vaccinations in general. The K-One Group will sell the LDV syringes with needle as an authorised representative of Anhui Kangda Medical Products Co. Ltd. based in China with the LDV syringes with needle approved under K-One MediTech Sdn. Bhd. by MDA. The MDA has approved twelve LDV syringes with needle in total, consisting of 1ml and 3 ml LDV syringes respectively with each having six different combinations of needle gauges (ranging from 23G to 25G) and lengths (ranging from 19 mm to 38 mm) to suit various market requirements. The approval of the LDV syringes with needle is timely as the Malaysian government is stepping up the rollout of the COVID-19 vaccinations in the coming months in the fight against rising infections by pushing for herd immunity through vaccinations. The demand for LDV syringes with needle is expected to increase in tandem with the accelerated rollout of COVID-19 vaccinations in the months ahead. In this regard, the K-One Group is prepared to cater to the surge in requirements of LDV syringes with needle. Reported Earnings • Apr 26
Full year 2020 earnings released: RM0.012 loss per share (vs RM0.008 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: RM91.2m (down 6.0% from FY 2019). Net loss: RM8.78m (down 244% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 01
New 90-day low: RM0.30 The company is down 22% from its price of RM0.39 on 01 December 2020. The Malaysian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 22% over the same period. Reported Earnings • Feb 26
Full year 2020 earnings released: RM0.012 loss per share (vs RM0.008 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: RM91.2m (down 6.0% from FY 2019). Net loss: RM8.81m (down 244% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 02
New 90-day low: RM0.33 The company is down 8.0% from its price of RM0.35 on 04 November 2020. The Malaysian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 25% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: RM0.33 The company is down 11% from its price of RM0.37 on 24 September 2020. The Malaysian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 18% over the same period. Reported Earnings • Nov 27
Third quarter 2020 earnings released: EPS RM0.001 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: RM23.9m (down 12% from 3Q 2019). Net income: RM523.0k (down 65% from 3Q 2019). Profit margin: 2.2% (down from 5.6% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Annonce • Nov 18
G-AsiaPacific (S) Pte Ltd Enters into an Agreement to Provide Amazon Web Services Cloud Services The Board of Directors of K-One Technology Berhad announced that on 13 November 2020, G-AsiaPacific (S) Pte Ltd. a wholly owned subsidiary of G-AsiaPacific Sdn Bhd, which in turn is wholly owned by K-One Tech, has entered into an agreement to provide Amazon Web Services cloud services to a new customer based in Singapore with minimum average contract value of approximately MYR 10 million per year for 3 years i.e. total of MYR 30 million, commencing 01 December 2020 till 30 November 2023. Is New 90 Day High Low • Nov 02
New 90-day low: RM0.34 The company is down 43% from its price of RM0.60 on 04 August 2020. The Malaysian market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 17% over the same period. Annonce • Oct 08
K-One Meditech Sdn Bhd Signs License Agreement with Star Syringe, Uk to Manufacture Syringe Safety Needle Cap in Malaysia & Distribute Worldwide The Board of Directors of K-One Technology Bhd announced that its wholly owned subsidiary, K-One MediTech Sdn Bhd has on 6 October 2020 signed a Licence Agreement with Star Syringe Ltd. based in the United Kingdom to manufacture syringe safety needle caps on an exclusive basis in Malaysia and distribute it worldwide on a non-exclusive basis. Is New 90 Day High Low • Sep 30
New 90-day low: RM0.35 The company is down 17% from its price of RM0.43 on 02 July 2020. The Malaysian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 42% over the same period.